J. Michael White

Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma.

A. Hauschild, D. Schadendorf, J. Kirkwood, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group.

G. Linette, J. Sosman, J. Kirkwood, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.